Navigation path

Pharmaceuticals - Community Register


Community register of orphan medicinal products


Product information

Doxorubicin polyisohexylcyanoacrylate nanoparticles

EU orphan designation number: EU/3/04/229   
Active ingredient: Doxorubicin polyisohexylcyanoacrylate nanoparticles
Indication: Treatment of the hepatocellular carcinoma
Sponsor: BioAlliance Pharma
49 boulevard du Général Martial Valin, F-75015 Paris, France

   Public summary of scientific opinion    


European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
25/10/2004 Centralised Orphan - Designation EMEA/OD/048/04 (2004)4226 of 21/10/2004
20/01/2009 Other procedure